Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs

Manil Kukar1, Olga Petryna1, Petros Efthimiou21Rheumatology Division, Lincoln Medical and Mental Health Center, New York, NY, USA; 2Lincoln Medical and Mental Health Center, Weill Cornell Medical College, New York, NY, USAAbstract: Enhanced understanding of the rheumatoid arthritis (RA) pathophysiol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Manil Kukar, Olga Petryna, Petros Efthimiou
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/a0cbd0044e1a4716986f4320d44f5f9b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a0cbd0044e1a4716986f4320d44f5f9b
record_format	dspace
spelling	oai:doaj.org-article:a0cbd0044e1a4716986f4320d44f5f9b2021-12-02T07:15:43ZBiological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs1177-54751177-5491https://doaj.org/article/a0cbd0044e1a4716986f4320d44f5f9b2009-09-01T00:00:00Zhttp://www.dovepress.com/biological-targets-in-the-treatment-of-rheumatoid-arthritis-a-comprehe-a3581https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Manil Kukar1, Olga Petryna1, Petros Efthimiou21Rheumatology Division, Lincoln Medical and Mental Health Center, New York, NY, USA; 2Lincoln Medical and Mental Health Center, Weill Cornell Medical College, New York, NY, USAAbstract: Enhanced understanding of the rheumatoid arthritis (RA) pathophysiology and the role of cytokines has enabled the development of innovative biological agents in the last 10 years that target specific parts of the immune response. Failure to achieve adequate response with traditional disease modifying anti-rheumatic drugs (DMARDs) and increasing evidence of ongoing radiographic deterioration of the affected joints despite seemingly clinical response were essential stimuli for the development of biologics. The current and upcoming biological agents are primarily aimed at neutralizing circulating and cell-bound pro-inflammatory cytokines, interfering in the interaction of antigen-presenting and T-lymphocytes, eliminating circulating B-lymphocytes or by interfering with the intracellular signaling mechanisms of immuno-competent cells that lead to inflammation. These agents have improved the currently available treatments due to greater efficacy, fast action and greater tolerability. However, use of these agents has also been associated with significant, although rare, adverse events and considerable cost. Therefore, these agents should be used with caution by experienced clinicians. The present work aims to provide a global and updated review of the current and in-development biological DMARDs for the treatment of RA.Keywords: biological agents, rheumatoid arthritis, immunomodulators, treatment, cytokines Manil KukarOlga PetrynaPetros EfthimiouDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 443-457 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Manil Kukar Olga Petryna Petros Efthimiou Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
description	Manil Kukar1, Olga Petryna1, Petros Efthimiou21Rheumatology Division, Lincoln Medical and Mental Health Center, New York, NY, USA; 2Lincoln Medical and Mental Health Center, Weill Cornell Medical College, New York, NY, USAAbstract: Enhanced understanding of the rheumatoid arthritis (RA) pathophysiology and the role of cytokines has enabled the development of innovative biological agents in the last 10 years that target specific parts of the immune response. Failure to achieve adequate response with traditional disease modifying anti-rheumatic drugs (DMARDs) and increasing evidence of ongoing radiographic deterioration of the affected joints despite seemingly clinical response were essential stimuli for the development of biologics. The current and upcoming biological agents are primarily aimed at neutralizing circulating and cell-bound pro-inflammatory cytokines, interfering in the interaction of antigen-presenting and T-lymphocytes, eliminating circulating B-lymphocytes or by interfering with the intracellular signaling mechanisms of immuno-competent cells that lead to inflammation. These agents have improved the currently available treatments due to greater efficacy, fast action and greater tolerability. However, use of these agents has also been associated with significant, although rare, adverse events and considerable cost. Therefore, these agents should be used with caution by experienced clinicians. The present work aims to provide a global and updated review of the current and in-development biological DMARDs for the treatment of RA.Keywords: biological agents, rheumatoid arthritis, immunomodulators, treatment, cytokines
format	article
author	Manil Kukar Olga Petryna Petros Efthimiou
author_facet	Manil Kukar Olga Petryna Petros Efthimiou
author_sort	Manil Kukar
title	Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
title_short	Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
title_full	Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
title_fullStr	Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
title_full_unstemmed	Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
title_sort	biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/a0cbd0044e1a4716986f4320d44f5f9b
work_keys_str_mv	AT manilkukar biologicaltargetsinthetreatmentofrheumatoidarthritisacomprehensivereviewofcurrentandindevelopmentbiologicaldiseasemodifyingantirheumaticdrugs AT olgapetryna biologicaltargetsinthetreatmentofrheumatoidarthritisacomprehensivereviewofcurrentandindevelopmentbiologicaldiseasemodifyingantirheumaticdrugs AT petrosefthimiou biologicaltargetsinthetreatmentofrheumatoidarthritisacomprehensivereviewofcurrentandindevelopmentbiologicaldiseasemodifyingantirheumaticdrugs
_version_	1718399530347528192

Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs

Ejemplares similares